3,4-Dimethoxybenzaldehyde

3,4-Dimethoxybenzaldehyde

SCHEMBL2370925

[2H]C([2H])([2H])Oc1ccc(C=O)cc1OC([2H])([2H])[2H]

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.74
TSHR P16473 1/20 0.74
FDPS P14324 1/20 0.58
TTR P02766 1/20 0.53
HPGD P15428 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
AOX1 Q06278 1/20 0.52
TRIM24 O15164 1/20 0.52
ALDH5A1 P51649 1/20 0.52
ABAT P80404 1/20 0.52
TRIM33 Q9UPN9 1/20 0.52
MAPT P10636 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
HTT P42858 2/20 0.50
LMNA P02545 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ALDH1A3 P47895 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3,4-Dimethoxybenzaldehyde SCHEMBL13290624 0.96 ALDH1A1 (0.81) ALDH1A1TSHRFDPSTTRHPGD
3,4-Dimethoxybenzaldehyde SCHEMBL2370931 0.96 ALDH1A1 (0.81) ALDH1A1TSHRFDPSTTRHPGD
3,4-Dimethoxybenzaldehyde SCHEMBL2529644 0.86 ALDH1A1 (0.55) ALDH1A1TSHRFDPSTTRHPGD
SCHEMBL703866 0.86 ALDH1A1 (0.62) ALDH1A1TSHRFDPSHPGDTDP1
3,4-Dimethoxybenzaldehyde SCHEMBL29364994 0.85 ALDH1A1 (1.00) ALDH1A1TSHRFDPSTTRHPGD
3,4-Dimethoxybenzaldehyde SCHEMBL25202 0.85 ALDH1A1 (1.00) ALDH1A1TSHRFDPSTTRHPGD
3,4-Dimethoxybenzaldehyde SCHEMBL5308959 0.85 ALDH1A1 (1.00) ALDH1A1TSHRFDPSTTRHPGD
3,4-Dimethoxybenzaldehyde SCHEMBL1330962 0.85 ALDH1A1 (1.00) ALDH1A1TSHRFDPSTTRHPGD
SCHEMBL15580939 0.85 ALDH1A1 (0.53) ALDH1A1TSHRFDPSTTRHPGD
SCHEMBL702720 0.84 ALDH1A1 (0.53) ALDH1A1TSHRFDPSTTRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116969936-A BCL-2 inhibitors 百济神州有限公司 2023-10-31 CN disclosed
CN-116802179-A BCL-2 inhibitors 百济神州有限公司 2023-09-22 CN disclosed
EP-4136084-A1 BCL-2 INHIBITOR BeiGene, Ltd. (KY) 2023-02-22 EP disclosed
US-8575221-B2 Derivatives of dimethylcurcumin CONCERT PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8084464-B2 Tetrahydroisoquinoline derivatives CONCERT PHARMACEUTICALS, INC. (US) 2011-12-27 US disclosed
US-8084464-B2 Tetrahydroisoquinoline derivatives CONCERT PHARMACEUTICALS, INC. (US) 2011-12-27 US disclosed
US-20110257271-A1 DERIVATIVES OF DIMETHYLCURCUMIN CONCERT PHARMACEUTICALS, INC. 2011-10-20 US disclosed
WO-2011116066-A1 DERIVATIVES OF DIMETHYLCURCUMIN CONCERT PHARMACEUTICALS, INC. (US) 2011-09-22 WO disclosed
EP-2231155-A1 TETRAHYDROISOQUINOLINE DERIVATIVES Concert Pharmaceuticals Inc. (US) 2010-09-29 EP disclosed
US-20100160351-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS NUON THERAPEUTICS, INC. (US) 2010-06-24 US disclosed
US-20100158905-A1 COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST NUON THERAPEUTICS, INC. (US) 2010-06-24 US disclosed
US-20090192188-A1 TETRAHYDROISOQUINOLINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2009-07-30 US disclosed
US-20090192188-A1 TETRAHYDROISOQUINOLINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2009-07-30 US disclosed
WO-2009079637-A1 TETRAHYDROISOQUINOLINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192188-A1 TETRAHYDROISOQUINOLINE DERIVATIVES HCRTR2, HCRTR1, OXTR ALDH1A1 1612/4885TSHR 932/4885FDPS 4517/4885
US-20110257271-A1 DERIVATIVES OF DIMETHYLCURCUMIN UROD, UGT1A1, UGT1A3 ALDH1A1 319/4885TSHR 4266/4885FDPS 153/4885
US-20100158905-A1 COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST PTGS2, PTGES2, PTGES ALDH1A1 351/4885TSHR 2986/4885FDPS 1743/4885
US-20100160351-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS XDH, SLC10A1, SLC10A6 ALDH1A1 488/4885TSHR 1570/4885FDPS 1369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.